Tissue Genesis Icellator Cell Isolation System
Tissue Genesis, Inc., Hawaii, United States
Tissue Genesis Icellator Cell Isolation System is an enabling technology. It is a compact automated desktop unit that utilizes liposuctioned adipose tissue to isolate millions of regenerative cells in about an hour. There are additional products in development supported by an SBIR.
Primary Application Area: Biotech & Biological Sciences
Technology Development Status: Ready to Market
Technology Readiness Level: TRL 9
FIGURES OF MERIT
Value Proposition: Tissue Genesis is the furthest along in US FDA Clinical trials. It plans to finish its Pilot study shortly and apply for a Pivotal Study to bring its technology to market in the US.
Organization Type: Mid-stage Startup (A or B)
GOVT/EXTERNAL FUNDING SOURCES
Government Funding/Support to Date: Tissue Genesis has raised over $50 million to fund its research, development and commercialization activities. In that amount, $32 million has been generated from a pipeline of federal contracts. An additional $7 million is expected over the next two years. Tissue Genesis has received over $23 million from private equity investors, including HMSA, a large Blue Cross and Blue Shield member; Bank of Hawaii; Servco Pacific, Inc.; prominent Silicon Valley technology investor, Berg &amp;amp; Berg Enterprises, LLC (an affiliate of Carl Berg); and Comprehensive Financial Management Group. The Company has leveraged this capital to achieve rapid progress from concept to clinical therapies using its advanced point-of-care technology and the recruitment of world-class research and clinical teams for successfully translation to the clinic.
Primary Sources of Funding: Other
Looking for: Both Funding and Development Partners